Hidayat Hussain,Ahmed Al-Harrasi,Ahmed Al-Rawahi et al.
Hidayat Hussain et al.
Introduction: Anthraquinones are aromatic compounds whose structures are related to anthracene (parent structure: 9,10-dioxoanthracene) for which various methods for their synthesis have been developed. In the past decade...
Nanoparticles for controlled release of anti-biofilm agents WO2014130994 (A1): a patent evaluation [0.03%]
用于控制释放抗生物膜剂的纳米粒子WO2014130994（A1）：一项专利评估
Claudiu T Supuran
Claudiu T Supuran
Nanoparticles based on poly(dimethylaminoethyl methacrylate)-b-poly(dimethylaminoethyl methacrylate-co-propylacrylic acid-co-butyl methacrylate) (p-DMAEMA-b-(DMAEMA-co-PAA-co-BMA)) were loaded with farnesol or apigenin for the controlled, p...
Podophyllotoxin derivatives: a patent review (2012 - 2014) [0.03%]
ポドフィロトキシン誘導体：特許総説（2012年〜2014年）
注意：提供的日语翻译并不是中文翻译，按照要求应该提供的是中文翻译。正确的中文翻译应该是：
波多菲林醇衍生物：专利回顾（2012-2014）
但根据您的要求和原始文本内容，准确的中文标题应为：
波多菲林醇衍生物：专利综述（2012-2014）
Ahmed Kamal,Syed Mohammed Ali Hussaini,Abdul Rahim et al.
Ahmed Kamal et al.
Introduction: Podophyllotoxin (PPT) is a naturally occurring antimitotic agent and an interesting lead in the development of anticancer agents. Its optimization led to the development of etoposide and teniposide used in c...
Paul M Njaria,John Okombo,Nicholas M Njuguna et al.
Paul M Njaria et al.
Introduction: Chloroquine (CQ) has been well known for its antimalarial effects since World War II. However, it is gradually being phased out from clinical use against malaria due to emergence of CQ-resistant Plasmodium f...
Alma Martelli,Lara Testai,Maria Cristina Breschi et al.
Alma Martelli et al.
Introduction: Hypertension represents a substantial cardiovascular risk factor. Among anti-hypertensive drugs, diuretics play an important role. Nevertheless, they present adverse effects such as hypokalemia or hyperkalem...
c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014) [0.03%]
c-Jun氨基末端激酶抑制剂：专利回顾（2010-2014）
Matthias Gehringer,Felix Muth,Pierre Koch et al.
Matthias Gehringer et al.
Introduction: c-Jun N-terminal kinases (JNKs) are involved in the emergence and progression of diverse pathologies such as neurodegenerative, cardiovascular and metabolic disorders as well as inflammation and cancer. In r...
Small molecule inhibitor of apoptosis proteins antagonists: a patent review [0.03%]
抗凋亡蛋白的小分子抑制剂：一项专利回顾
Alexander W Hird,Brian M Aquila,Edward J Hennessy et al.
Alexander W Hird et al.
Introduction: The family of inhibitor of apoptosis proteins (IAPs) plays a key role in the suppression of proapoptotic signaling; hence, a small molecule that disrupts the binding of IAPs with their functional partner sho...
Small-molecule anti-inflammatory drug compositions for the treatment of asthma: a patent review (2013 - 2014) [0.03%]
哮喘小分子抗炎药物制剂的专利评审（2013-2014）
Paul Glossop,Gavin Whitlock,Karl Gibson
Paul Glossop
Introduction: Asthma is a chronic condition affecting 235 million people worldwide, with prevalence continuing to increase. A significant number of patients have poorly controlled asthma but despite this, a new mechanisti...
Evaluation of US20150011555. An inhaled IP receptor agonist for the treatment of pulmonary arterial hypertension [0.03%]
US20150011555的评估。一种用于治疗肺动脉高压的吸入IP受体激动剂
Peter Norman
Peter Norman
Introduction: Pulmonary arterial hypertension (PAH) is a rare disease for which IP receptor agonists provide one of the main classes of treatment. Currently available agents tend to lack receptor selectivity. ...
F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review [0.03%]
F508del-囊性纤维化跨膜调节器纠偏治疗囊性纤维化：一项专利回顾
Hong Yang,Tonghui Ma
Hong Yang
Introduction: Cystic fibrosis (CF) is an autosomal recessive genetic disease caused by malfunction of CF transmembrane regulator (CFTR). The deletion of a phenylalanine at residue 508 (F508del) is the most common mutation...